BioInvent International is at the forefront of cancer therapy development, leveraging its proprietary technologies to create innovative immuno-oncology drug candidates. Central to its approach is the F.I.R.S.T™ platform, which utilizes patient-derived materials to identify clinically relevant targets and corresponding antibodies. This patient-centered methodology allows for the simultaneous exploration of antibody binding to both diseased and healthy tissues, ensuring the selection of antibodies that are uniquely effective against cancer. Additionally, BioInvent's n-CoDeR® antibody library, which contains over 30 billion human antibody genes, enables the identification of specific antibodies through advanced phage display technology. This extensive library supports the development of antibodies that can effectively target various cancer-related proteins.

BioInvent's clinical pipeline includes promising candidates like BI-1206, a monoclonal antibody designed to enhance the efficacy of existing treatments for non-Hodgkin lymphoma (NHL) by blocking the inhibitory Fc receptor CD32B (FcγRIIB). This approach aims to restore the activity of rituximab, a cornerstone therapy for NHL, particularly in patients who have become resistant to treatment. The ongoing Phase 1/2a trials for BI-1206, in combination with rituximab and acalabrutinib, are expected to yield preliminary data by the end of 2024, highlighting BioInvent's commitment to advancing cancer therapies that can significantly improve patient outcomes.

Sweden

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Cancer

Immune System Diseases

Lymphatic Diseases

BioInvent International

Solid tumor/s

BI-1808 (TNFR2)

Antibodies

Biologics

Small Molecule Pharmaceuticals

Advanced malignancies

BI-1808 +/- KEYTRUDA

Non-Hodgkin lymphoma

BI-1206 +/- rituximab & acalabrutinib

<p class="font_8">BI-1910 is BioInvent’s second tumor necrosis factor receptor 2 (TNFR2) program</p>

BioInvent International

Company Details